Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtu...
May 13 2020 - 7:00AM
Trillium Therapeutics Inc. (“Trillium” or the “Company”)
(NASDAQ/TSX: TRIL), a clinical stage immuno-oncology
company developing innovative therapies for the treatment of
cancer, will present data on its novel CD47 checkpoint inhibitor,
TTI-622, at the Developmental Therapeutics Session of the ASCO20
Virtual Scientific Program to be held May 29-31, 2020. The
presentation will highlight a first-in-human study evaluating
TTI-622 in patients with advanced relapsed or refractory lymphoma.
Presentation details are as follows:
Presenter: Krish Patel,
MDTitle: Ongoing, First-in-human, Phase 1 Dose
Escalation Study of the Investigational CD47-blocker TTI-622 in
Patients with Advanced Relapsed or Refractory Lymphoma
Session: Developmental Therapeutics -
ImmunotherapyAbstract: 3030Session
Type: Poster Presentation (Poster #94)
The poster will be available on the meeting
website beginning Friday, May 29 at 8:00 am ET. A
copy of the poster will also be available on the Events and
Presentations page of Trillium’s website.
About Trillium Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
Company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “do not eat” signal that cancer cells frequently use to
evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Company Contact:James
ParsonsChief Financial OfficerTrillium Therapeutics Inc.
416-595-0627
x232james@trilliumtherapeutics.comwww.trilliumtherapeutics.com
Media Relations:Mike Beyer Sam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jul 2023 to Jul 2024